GSK buys US biopharma company Nuvalent for $10.6B
Source ↗
👁 1
💬 0
British pharmaceutical giant GlaxoSmithKline (GSK) has announced its acquisition of US-based biopharmaceutical company Nuvalent for $10.6 billion.
The deal, which marks GSK's first major transaction under CEO Luke Miels, will see the British drugmaker pay $124 per share in cash, a 40% premium to Nuvalent's closing share price on Monday.
After accounting for cash acquired, GSK's total investment in the deal is estimated at around $9.4 billion.
The deal, which marks GSK's first major transaction under CEO Luke Miels, will see the British drugmaker pay $124 per share in cash, a 40% premium to Nuvalent's closing share price on Monday.
After accounting for cash acquired, GSK's total investment in the deal is estimated at around $9.4 billion.
Comments (0)